Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease

被引：8

作者：

Chen, Huanhua ^{[1
]}

Gao, Xudong ^{[3
]}

Li, Xinzhu ^{[2
]}

Yu, Chong ^{[1
]}

Liu, Wenwu ^{[1
]}

Qiu, Jingsong ^{[1
]}

Liu, Wenjie ^{[1
]}

Geng, Hefeng ^{[2
]}

Zheng, Fangyuan ^{[2
]}

Gong, Hao ^{[1
]}

Xu, Zihua ^{[1
]}

Jia, Jingming ^{[1
]}

Zhao, Qingchun ^{[1
,2
,3
]}

机构：

[1] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Shenyang 110016, Liaoning, Peoples R China

[2] Shenyang Pharmaceut Univ, Sch Life Sci & Biochem, Shenyang 110016, Liaoning, Peoples R China

[3] Gen Hosp Northern Theater Command, Dept Pharm, Shenyang 110840, Peoples R China

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 15期

基金：

中国国家自然科学基金;

关键词：

GLYCOGEN-SYNTHASE KINASE-3; SPATIAL MEMORY IMPAIRMENT; DOWN-SYNDROME; TAU-PHOSPHORYLATION; DYRK1A INHIBITOR; DRUG DISCOVERY; PROTEIN; MECHANISM; SUPPORT; RESCUES;

D O I：

10.1021/acs.jmedchem.4c00483

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has been verified to regulate the progression of tau pathology as a promising treatment for Alzheimer's disease (AD), while the research progress on DYRK1A inhibitors seemed to be in a bottleneck period. In this work, we identified 32 (ZJCK-6-46) as the most potential DYRK1A inhibitor (IC50 = 0.68 nM) through rational design, systematic structural optimization, and comprehensive evaluation. Compound 32 exhibited acceptable in vitro absorption, distribution, metabolism, and excretion (ADME) properties and significantly reduced the expression of p-Tau Thr212 in Tau (P301L) 293T cells and SH-SY5Y cells. Moreover, compound 32 showed favorable bioavailability, blood-brain barrier (BBB) permeability, and the potential of ameliorating cognitive dysfunction by obviously reducing the expression of phosphorylated tau and neuronal loss in vivo, which was deserved as a valuable molecular tool to reveal the role of DYRK1A in the pathogenesis of AD and to further promote the development of anti-AD drugs.

引用

页码：12571 / 12600

页数：30

共 65 条

[1]

Avila J, 2010, EXPERT REV NEUROTHER, V10, P703, DOI [10.1586/ern.10.40, 10.1586/ERN.10.40]

[2] High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation [J].

Azorsa, David O. ;

Robeson, RiLee H. ;

Frost, Danielle ;

Hoovet, Bessie Meec ;

Brautigam, Gillian R. ;

Dickey, Chad ;

Beaudry, Christian ;

Basu, Gargi D. ;

Holz, David R. ;

Hernandez, Joseph A. ;

Bisanz, Kristen M. ;

Gwinn, Leslie ;

Grover, Andrew ;

Rogers, Joseph ;

Reiman, Eric M. ;

Hutton, Michael ;

Stephan, Dietrich A. ;

Mousses, Spyro ;

Dunckley, Travis .

BMC GENOMICS, 2010, 11

[3] Advances in synthesis and biological activities of quinazoline scaffold analogues: A review [J].

Boddapati, S. N. Murthy ;

Bollikolla, Hari Babu ;

Bhavani, K. Geetha ;

Saini, Harshdeep Singh ;

Ramesh, Navudu ;

Jonnalagadda, Sreekantha Babu .

ARABIAN JOURNAL OF CHEMISTRY, 2023, 16 (10)

[4] Dyrk1 inhibition improves Alzheimer's disease-like pathology [J].

Branca, Caterina ;

Shaw, Darren M. ;

Belfiore, Ramona ;

Gokhale, Vijay ;

Shaw, Arthur Y. ;

Foley, Christopher ;

Smith, Breland ;

Hulme, Christopher ;

Dunckley, Travis ;

Meechoovet, Bessie ;

Caccamo, Antonella ;

Oddo, Salvatore .

AGING CELL, 2017, 16 (05) :1146-1154

[5] Neuroprotective effect of transient receptor potential Vanilloid 1 agonist capsaicin in Alzheimer?s disease model induced with okadaic acid [J].

Cakir, Murat ;

Yuksel, Furkan ;

Ozkut, Mahmud Mustafa ;

Durhan, Merve ;

Kaymak, Emin ;

Tekin, Suat ;

Cigremis, Yilmaz .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118

[6] An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f]quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases [J].

Chaikuad, Apirat ;

Diharce, Julien ;

Schroeder, Martin ;

Foucourt, Alicia ;

Leblond, Bertrand ;

Casagrande, Anne-Sophie ;

Desire, Laurent ;

Bonnet, Pascal ;

Knapp, Stefan ;

Besson, Thierry .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (22) :10315-10321

[7] A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro [J].

Coutadeur, Severine ;

Benyamine, Helene ;

Delalonde, Laurence ;

Oliveira, Catherine de ;

Leblond, Bertrand ;

Foucourt, Alicia ;

Besson, Thierry ;

Casagrande, Anne-Sophie ;

Taverne, Thierry ;

Girard, Angelique ;

Pando, Matthew P. ;

Desire, Laurent .

JOURNAL OF NEUROCHEMISTRY, 2015, 133 (03) :440-451

[8] Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development [J].

Dang, T. ;

Duan, W. Y. ;

Yu, B. ;

Tong, D. L. ;

Cheng, C. ;

Zhang, Y. F. ;

Wu, W. ;

Ye, K. ;

Zhang, W. X. ;

Wu, M. ;

Wu, B. B. ;

An, Y. ;

Qiu, Z. L. ;

Wu, B. L. .

MOLECULAR PSYCHIATRY, 2018, 23 (03) :747-758

[9] Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans [J].

De la Torre, Rafael ;

De Sola, Susana ;

Pons, Meritxell ;

Duchon, Arnaud ;

Martinez de lagran, Maria ;

Farre, Magi ;

Fito, Montserrat ;

Benejam, Bessy ;

Langohr, Klaus ;

Rodriguez, Joan ;

Pujadas, Mitona ;

Charles Bizot, Jean ;

Cuenca, Aida ;

Janel, Nathalie ;

Catuara, Silvina ;

Isabel Covas, Maria ;

Blehaut, Henri ;

Herault, Yann ;

Marie Delabar, Jean ;

Dierssen, Mara .

MOLECULAR NUTRITION & FOOD RESEARCH, 2014, 58 (02) :278-288

[10] Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B [J].

Deau, Emmanuel ;

Lindberg, Mattias F. F. ;

Miege, Freïdeïric ;

Roche, Didier ;

George, Nicolas ;

George, Pascal ;

Kra''mer, Andreas ;

Knapp, Stefan ;

Meijer, Laurent .

JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) :10694-10714

← 1 2 3 4 5 6 7 →